Delving into the Latest Updates on Shanghai Maiji Biotechnology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Shanghai Maiji Biotechnology Co., Ltd. is a leading biotechnology company specializing in the research, development, production, and sales of high-quality bio-products. With a strong focus on innovation and technology, Maiji Biotechnology continuously invests in R&D and strives to stay at the forefront of the biotechnology industry. Founded in 2004 and headquartered in Shanghai, China, Maiji Biotechnology has offices and production facilities in multiple locations worldwide.

Tags

Respiratory Diseases

Immune System Diseases

Skin and Musculoskeletal Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	4
Neoplasms	2
Infectious Diseases	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	9

Top 5 Target	Count

IL-4Rα(Interleukin-4 receptor subunit alpha)	1
IL-33(Interleukin-33)	1
TSLP(Thymic stromal lymphopoietin)	1
MASP2(Mannan-binding lectin serine protease 2)	1

Primary objective: Compared with placebo, to evaluate the efficacy of MG-K10 monotherapy in adult patients with moderate to severe atopic dermatitis (AD). Secondary objective: Compared with placebo, to evaluate the safety of MG-K10 monotherapy in adult patients with moderate to severe AD. Evaluate the PK characteristics, PD characteristics and immunogenicity of MG-K10.

Start Date29 Dec 2023

Sponsor / Collaborator

Shanghai Maiji Biotechnology Co., Ltd.

CTR20232822 / CompletedPhase 1

MG-K10人源化单抗注射液在健康成人受试者中的药代动力学特征比较的随机、开放、平行入组的I期临床研究

[Translation] A randomized, open, parallel-group phase I clinical study comparing the pharmacokinetic characteristics of MG-K10 humanized monoclonal antibody injection in healthy adult subjects

主要目的：比较单次皮下注射MG-K10后在中国健康成人受试者体内的药代动力学特征；次要目的评估单次皮下注射MG-K10在中国健康成人受试者中的安全性和耐受性；评估MG-K10在中国健康成人受试者体内的免疫原性。

[Translation]

Primary objective: To compare the pharmacokinetic characteristics of MG-K10 in healthy Chinese adult subjects after a single subcutaneous injection; Secondary objective To evaluate the safety and tolerability of a single subcutaneous injection of MG-K10 in healthy Chinese adult subjects; To evaluate the immunogenicity of MG-K10 in healthy Chinese adult subjects.

Start Date23 Oct 2023

Sponsor / Collaborator

Shanghai Maiji Biotechnology Co., Ltd.

100 Clinical Results associated with Shanghai Maiji Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Maiji Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Maiji Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Maiji Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Oct 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

4

Preclinical

Phase 1 Clinical

3

1

Phase 3 Clinical

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Comekibart ( IL-4Rα )	Dermatitis, Atopic More	Phase 3
MG-014 ( TSLP )	Pulmonary Disease, Chronic Obstructive More	Phase 1
MG-013 ( MASP2 )	Glomerulonephritis, IGA More	Phase 1
MG-ZG122	Asthma More	Phase 1
MG-015	Fibrosis More	Preclinical